Navigation Links
CNA Finance Provides Research Update On Aytu Bioscience And Natesto®
Date:8/17/2017

CNA Finance Chief Research Analyst, Kenny Soulstring, today announced that the stock market news outlet had provided a research update on Aytu Bioscience and cited promising increases in the prescription rates for Natesto®, the company's nasally administered TRT product.

According to Soulstring, prescription rates for Natesto® have more than doubled since March of this year and on a sequential basis, month over month, Natesto® prescription rates have jumped to 593 for the month of June, Aytu's fourth consecutive month of increased prescription levels, representing an increase in excess of 100% during the prior four months.

According to Soulstring, he believes that shares of Aytu Bioscience are under undue pressure due to factors associated with its recent private placement, which provided warrant options as part of the package. In contrast to market sentiment, Soulstring believes that current price levels may offer a tremendous opportunity to purchase shares of Aytu at discounted prices.

Kenny Soulstring commented, "First and foremost, the company is now well capitalized and has ample cash for the next four quarters of business. Combined with the sharp increases in Natesto® prescription rates, the company may be on track to become a profitable company by the end of 2018." He added, "Investors that understand the market pressures from any dilutive financing also know that in many cases the market overshoots what a natural level of share decline should be, and I believe that is the case investors are witnessing for the current share price of Aytu Bioscience."

As noted in a detailed release by CNA Finance, sales of Natesto® have increased on a sequential basis for the previous four months, remains the ONLY available TRT product that does not require an FDA mandated Black Box warning, and has proven itself more effective and significantly safer than competing and available products on the market.

Soulstring also believes that once the momentum materializes for insurance reimbursement, sales of Natesto® have an opportunity to ramp significantly, and with its focused, and credentialed sales force may be in a position to capture at least 5% of the $2 billion market potential.

To view Kenny Soulstring's full analysis of Aytu Bioscience and Natesto®, click here.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14597469.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
2. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
3. Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
4. ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria
5. iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare
6. Neurotez Engages Invictus Global Capital as Corporate Finance & Capital Markets Advisors
7. Revenue Leak Soon Turns to Flood: Payment Penalties for High Infection Rates Draining Hospital Finances
8. Yew Bio-Pharm Group Signs Sales Agreement and Receives Subsidy Grant from the Finance Department of Heilongjiang Province, China
9. Oxford Finance Closes $20 Million Debt Facility with Inhibrx
10. Oxford Finance Provides $10 Million Debt Financing to Celula
11. CSM Appoints Michael Morse as Vice President of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... ... of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials that ... human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will radically ...
(Date:9/14/2017)... , ... September 14, 2017 , ... One of the ... Saturday, Sept. 16. , For six hours that day, the GenCure Marrow Donor Program ... more than 30 H-E-B grocery stores in San Antonio. , The registration tables will ...
(Date:9/13/2017)... ... September 13, 2017 , ... AMRI, a global contract ... patient outcomes and quality of life for more than 25 years, today announced ... expert to the International Standards Organization/Technical Committee 194: Biological and Clinical Evaluation ...
(Date:9/12/2017)... ... September 12, 2017 , ... Avomeen.com, the analytical ... and development companies will be exhibiting at the 16th annual Contract Pharma Conference ... Pharma is an educational conference for pharma and bio-pharma professionals that has ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
Breaking Biology News(10 mins):